25 Oct Katexco Pharmaceuticals To Develop Cannabis Derivative CBD to Suppress Inflammatory Conditions
Dr. Rothbard
MedicalResearch.com Interview with:
Jonathan Rothbard, MA, PhD
Steinman Lab Stanford Medicine
Co-founder Gold Bee – Pharmaceutical Grade CBD Products
MedicalResearch.com: What is the background for this new company? How did Katexco get its name?
Response: Researchers with Stanford University, Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors.
Katexco will work to develop the first drug to focus on a key receptor on immune cells that are involved in inflammatory disease. The first primary target indications include gastrointestinal disorders like Crohn’s disease, gout and multiple sclerosis.
Katexco is from the Greek word to restrain or regulate, and we are trying to restrain the immune system in inflammatory disease. We produce what Observer.com has ranked the #1 CBD oil for pain. In fact, our CBD oil is the best CBD oil for pain according to more than 300 independently verified reviews from consumers on TrustSpot.
MedicalResearch.com: How is Katexco is using the cannabis derivative CBD to develop treatments for inflammatory disorders?
Response: Medical marijuana has been proven effective for the treatment of inflammatory and autoimmune diseases. Behind that is the endocannabinoid system, lipid-based retrograde neurotransmitters that bind to cannabinoid receptors. Cannabinoid receptor proteins are expressed throughout the mammalian central nervous system, including the brain, and the peripheral nervous system, and these receptors are also found on immune cells outside the nervous system. (see citation below) CBD products such as oils, are being used frequently within the US population. There’s a lot of speculations around the time taken to see results from such CBD products.
Katexco plans to harness the properties of the endocannabinoid system and the nicotine receptor system (nAChRs), which respond to the neurotransmitter acetylcholine
MedicalResearch.com: What should readers take away from your report?
Response: Katexco plans to harness the properties of the endocannabinoid system and the nicotine receptor system (nAChRs), which respond to the neurotransmitter acetylcholine.
Citation:
Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects G. A. Cabral* and L. Griffin-Thomas Department of Microbiology and Immunology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, 23298, USA
Expert Rev Mol Med. ; 11: e3. doi:10.1017/S1462399409000957.
[wysija_form id=”3″]
[last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.